Bioqual

Bioqual Payout Ratio

The Dividend Payout Ratio of Bioqual (BIOQ) as of Oct 21, 2026 is 92.50 %. In the previous year, Dividend Payout Ratio was 53.52 % — a change of 72.82% (higher).

Payout Ratio

92.50 %

YoY

72.82%

Last updated:

Dividend Payout Ratio of Bioqual is 2024 92.50 % . Dividend Payout Ratio of Bioqual was 2023 53.52 % . It decreases by 72.82% higher compared to the previous year.

The payout ratio is around 54% of earnings.

The Bioqual Payout Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payout Ratio
Date
Payout Ratio
Jan 1, 2019
22.10 USD
Jan 1, 2020
23.24 USD
Jan 1, 2021
17.67 USD
Jan 1, 2022
17.00 USD
Jan 1, 2023
53.52 USD
Jan 1, 2024
92.50 USD
Jan 1, 2025
54.34 USD
Jan 1, 2026
66.79 USD
The Bioqual Payout Ratio history
YEARPayout RatioYoY
66.79 %+22.90%
54.34 %-41.25%
92.50 %+72.82%
53.52 %+214.80%
17.00 %-3.78%
17.67 %-23.97%
23.24 %+5.17%
22.10 %-59.33%
54.34 %+301.48%
13.53 %-3.10%
13.97 %-14.85%
16.40 %-20.30%
20.58 %-62.12%
54.34 %+52.25%
35.69 %+3.01%
34.65 %+217.88%
10.90 %-14.02%
12.68 %-76.67%
54.34 %0.00%
54.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioqual Stock analysis

What does Bioqual do? Bioqual Inc. is an emerging biotechnology company based in Maryland, USA. The company was founded in 1988 with the aim of developing innovative solutions and services for the life sciences and pharmaceutical industry. The founding of Bioqual is closely connected to the emergence of new technologies in the field of biotechnology and genomics research. The company has always been committed to developing innovative products and services that contribute to improving the diagnosis and treatment of diseases, accelerating or facilitating the development of new drugs, and enhancing the quality of animal testing. In its early years, Bioqual primarily focused on the development of diagnostic test systems for animal diseases. In the 1990s, the company expanded its scope to research on infectious diseases and vaccine development. Since 2000, Bioqual has shifted its focus to drug discovery and preclinical studies. Today, Bioqual offers a wide range of products and services in various areas. These include immunological assays, cell culture and microbiology laboratory services, preclinical studies and animal testing services, as well as support in the development of new drugs. An important business model of Bioqual is collaboration with other companies. The company is a key partner for biotech and pharmaceutical companies involved in the development of new drugs and therapies. Bioqual offers preclinical studies and animal testing services to test the effectiveness and safety of new drugs. Partner companies can thus pool their resources and accelerate the testing phase. Bioqual also has its own research and development department and collaborates with academic and medical institutions in the development of new diagnostic and therapeutic methods. Another important area for Bioqual is animal testing services. The company offers specialized animal testing services, including the creation of animal models, conducting studies on the efficacy, pharmacokinetics, and toxicity of substances, as well as regulatory consulting services. In recent years, Bioqual has expanded its presence in the field of diagnostics and treatment of infectious diseases. The company offers serological assays and PCR tests to diagnose infections caused by viruses, bacteria, and parasites. Additionally, Bioqual is involved in the development of vaccines against a variety of infectious diseases, including HIV, Hepatitis C, Zika, and West Nile Virus. The products and services of Bioqual are applied in various areas of life sciences and medicine. They are utilized by pharmaceutical and biotech companies, government agencies, academic institutions, and medical laboratories. Bioqual has shown strong growth in recent years. The company continuously invests in research and development of new products and services to meet the needs of its customers. The company also has a strong presence in various global markets, particularly in Europe, Asia, and South America. Bioqual has established a reputation as an innovative and reliable company in the biotechnology and pharmaceutical industry. With its wide range of products and services and close collaboration with other companies, Bioqual positions itself as a key partner in the development of new diagnostic and therapeutic methods, as well as the exploration of infectious diseases and new drugs. Bioqual is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioqual stock

Dividend Payout Ratio of Bioqual is 92.50 % in 2024.

Dividend Payout Ratio of Bioqual changed from 53.52 % to 92.50 %, representing a 72.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Dividend Payout Ratio Bioqual since 2006 – with annual values, charts, and detailed analysis.

The payout ratio measures the percentage of net income distributed as dividends. A sustainable payout ratio leaves room for reinvestment and growth.

Dividend Payout Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Payout Ratio's Bioqual historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Bioqual

All Key Metrics — Bioqual